Original ReportDexketoprofen Trometamol in the Acute Treatment of Migraine Attack: A Phase II, Randomized, Double-Blind, Crossover, Placebo-Controlled, Dose Optimization Study
Key words
Cited by (0)
The study was financially supported by Menarini Industrie Farmaceutiche Riunite through an unconditional and unrestricted grant. The funding source did not influence or commented on planned methods, protocol, data analysis and the draft report. The authors did not receive payments to themselves for the study. F.M. has occasionally served as scientific consultant for Istituto Lusofarmaco d'Italia-Menarini group, Almirall, Pfizer, Merck. G.Z. has occasionally served as scientific consultant for Menarini International Operations Luxembourg, Almirall, Pfizer, Merck, and Allergan. F.M. has occasionally served as scientific consultant for Almirall, Pfizer, and Merck. D.P. and D.Z. are employees of Istituto Lusofarmaco d'Italia–Menarini group.
The services of Primula (Dr. Selene Mogavero and Dr. Colin Gerard Egan) were paid by Istituto Lusofarmaco d'Italia, Menarini group to revise the English version of the manuscript.